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Résumé en
anglais
Aims  Thiazolidinediones (TZDs) are associated with a higher risk of bone fracture
in women compared with men. The aim of the present study was to investigate
whether TZDs could influence osteocyte behaviour and contribute to the skeletal
phenotype observed in TZD-treated patients.Methods  The murine MLO-Y4 cell line
was used as a source of osteocytes. These cells were cultured for 24 h with 0,
10−8 m, 10−7 m, 10−6 m, 10−5 m or 10−4 m of pioglitazone, rosiglitazone or
troglitazone in the presence or absence of 17β-oestradiol. The extent of osteocyte
apoptosis was assessed, as was the expression of the bone formation inhibitor
sclerostin and receptor activator for nuclear factor κB ligand (RANKL) also.Results 
In the absence of 17β-oestradiol, pioglitazone, rosiglitazone and troglitazone
induced osteocyte apoptosis dose-dependently even at the lowest concentration of
10−8 m. Furthermore, the expression of sclerostin but not RANKL was significantly
increased in TZD-treated cultures compared with untreated cultures. The presence
of 17β-oestradiol significantly reduced TZD-induced osteocyte apoptosis and also
sclerostin up-regulation.Conclusions  These findings therefore raise the potential
concern of using TZDs in post-menopausal women where the lack of oestrogen
would not prevent osteocyte apoptosis and sclerostin up-regulation and may
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